Genovis Launches GingisREX And Expands Product Portfolio

Genovis is launching GingisREX, a new enzyme aimed at customers throughout the proteomics market. The products that Genovis has launched to date have been used solely for modification of antibodies, while GingisREX can be used for proteins in general.

Genovis’ products are marketed under the name SmartEnzymes™ and are used in the biotech and pharmaceutical industries for characterization of biologics. What sets GingisREX apart from the other enzymes in the product portfolio is that the enzyme not only cleaves antibodies, it also cleaves other proteins specifically after the amino acid arginine. GingisREX is extremely reliable and more precise than similar enzymes on the market. It can be used alone or in combination with Genovis’ other enzymes to improve analysis results.

“With the launch of GingisREX we are now focusing on the entire proteomics market. Our customers currently use our enzymes for mass spec analysis and with GingisREX we have now expanded the range for this customer group, at the same time that we open up the available market. The product portfolio to date has only included enzymes for analysis of antibodies, but it is now expanding to include other proteins, and moving forward we intend to deliver several new enzymes for the entire proteomics market. This is both challenging and exciting,” says Fredrik Olsson, CEO of Genovis For more information about GingisREX

For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046 (0)46 -101233


Genovis’ business concept is to offer customers in the pharmaceutical and medical device industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA).

Back to news